Methylene Blue

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

亚甲蓝（IC50 为 1.9 μM）抑制 tau 丝形成。它抑制可溶性鸟苷酸环化酶。它也用作染色内窥镜检查的染料。

Methylene blue is a synthetic basic dye. Methylene blue stains to negatively charged cell components like nucleic acids; when administered in the lymphatic bed of a tumor during oncologic surgery, methylene blue may stain lymph nodes draining from the tumor, thereby aiding in the visual localization of tumor sentinel lymph nodes. When administered intravenously in low doses, this agent may convert methemoglobin to hemoglobin.(In Vitro):Methylene blue (Basic Blue 9) (4.5 μM; BV2 microglia) alters the immune profile of LPS-activated BV2 microglia and decreases the level of CD14, IL-1β, TNF-α, and CCL2 mRNA.(In Vivo):Methylene blue (Basic Blue 9) (50 and 100 mg/kg; i.p.; once, for 25 min; male NMRI mice) reduces absent prepulse inhibition. Methylene blue (Basic Blue 9) (20 and 40 mg/kg; p.o.; daily, for 6 months; CaMKIIα-tTA transactivator mice) preserves cognition in mice expressing full-length pro-aggregant human Tau.Methylene blue (Basic Blue 9) (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces TBI-induced edema and neuroinflammation and reduces acute depression-like behavior. Methylene blue (Basic Blue 9) (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces the percentage of inflammatory factor.

Methylene blue (Basic Blue 9) (4.5 μM; BV2 microglia) alters the immune profile of LPS-activated BV2 microglia and decreases the level of CD14, IL-1β, TNF-α, and CCL2 mRNA.

Methylene blue (Basic Blue 9) (50 and 100 mg/kg; i.p.; once, for 25 min; male NMRI mice) reduces absent prepulse inhibition.Methylene blue (Basic Blue 9) (20 and 40 mg/kg; p.o.; daily, for 6 months; CaMKIIα-tTA transactivator mice) preserves cognition in mice expressing full-length pro-aggregant human Tau.Methylene blue (Basic Blue 9) (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces TBI-induced edema and neuroinflammation and reduces acute depression-like behavior.Methylene blue (Basic Blue 9) (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces the percentage of inflammatory factor. Animal Model:Male NMRI mice Dosage:50 and 100 mg/kg Administration:Intraperitoneal injection; once, for 25 minutes Result:Reduced the prepulse inhibition and reduced the increase in locomotor activity caused by phencyclidine (PCP).Animal Model:CaMKIIα-tTA transactivator mice Dosage:20 and 40 mg/kg Administration:Oral administration; daily, for 6 months Result:Inhibited Tau aggregation in CaMKIIα-tTA transactivator mice.Animal Model:TBI-treated male BALB/c miceDosage:2 mg/kgAdministration:Intravenous injection; once, for 1 day Result:Decreased the level of CD14, IL-1β, TNF-α, and CCL2 mRNA. Animal Model:TBI-treated male BALB/c mice Dosage:2 mg/kg Administration:Intravenous injection; once, for 1 day Result:Reduced the percentage of myeloid (CD11b+/GR1+) cells, reduced IL-1β and enhanced IL-10 expression in microglia.

Methylene blue | CI52015

Apoptosis

NF-κB

Tau aggregation|guanylate cyclase

Others-Field

——

61-73-4

319.85

C16H18ClN3S

>98% (HPLC)

H2O : ≥ 50 mg/mL; 156.32 mM

[Cl-].CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C

3,7-bis(dimethylamino)phenothiazin-5-ium chloride

(-20℃)

With Ice Pack

≥ 2 years